Prior to joining U.S. Genomics, Mr. DeFalco was at PerkinElmer where he served as an officer in both business development and operating roles. His most recent position was President of PerkinElmer Instruments and Senior Vice President of PerkinElmer, Inc. While there, Mr. DeFalco led the acquisition and turnaround of the $500 Million revenue, 2,400 employee Instruments division. In this role, he launched over 30 new products and successfully completed a number of acquisitions and joint ventures. Mr. DeFalco drove an operations improvement program based on six sigma methodologies. These improvements were the basis of Reader’s Choice Awards from “Today’s Chemist at Work” for Quality in 2000 and for Technology Innovation in 2001.
Mr. DeFalco has also held executive positions at United Technologies, was a senior manager with McKinsey & Company in their high tech sector, and led engineering teams at IBM. Mr. DeFalco holds an MS in Management from the Sloan School of Management at MIT where he won the award for the most outstanding thesis in Marketing and the Alexander Proudfoot Award for academic excellence. Mr. DeFalco also holds an MS in Computer Engineering from Syracuse University, and a BS in Mechanical Engineering from MIT.
 

J. Craig Venter is the president of three newly formed not-for-profit organizations, The Center for the Advancement of Genomics, the Institute for Biological Energy Alternatives, and the J. Craig Venter Science Foundation. These organizations are dedicated to exploring social and ethical issues in genomics, as well as seeking alternative solutions to energy through microbial sources. In 1992, he and his wife, Dr. Claire Fraser, founded The Institute for Genomic Research known as TIGR, where he served as President and Chief Scientific Officer until 1998. In 1998 Dr. Venter founded Celera Genomics as a means to test the whole genome shotgun technique, new mathematical algorithms, as well as new automated DNA sequencing machines. Through his leadership as Chairman of the Board of TIGR and as a founder and former President of Celera Genomics, Dr. Venter has played a leading and vital role in genomics. His accomplishments in decoding the genetic sequences of other organisms, particularly the fruit fly and mouse, have also provided important scientific insights, including a new understanding of the genetic relationship between species. He has published more than 220 research articles and is among the most frequently cited scientists in biology and medicine. He earned a bachelor’s degree in biochemistry in 1972 and a Ph.D. in Physiology and Pharmacology in 1975, both from the University of California at San Diego.
 

Mr. Lawlor is a General Partner at HealthCare Ventures, one of the largest healthcare-focused venture capital firms in the world. Mr. Lawlor has 15 years of experience in the biotechnology industry in finance, business development, mergers and acquisitions, and general management. Prior to joining HCV in 2000, he was Chief Operating Officer of LeukoSite, a biotechnology company. Before joining LeukoSite, Mr. Lawlor was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technology. He was previously Chief Financial Officer and Vice President, Business Development of BioSurface Technology. Mr. Lawlor is co-founder of Phase Forward, a company developing Internet-based management tools for the conduct of clinical trials. Mr. Lawlor received a B.A. degree from the University of New Hampshire, where he was elected to Phi Beta Kappa, and a master's degree in Management from Yale University. He joined HCV in 2000.
 

Dr. Petrillo has been a Director of U.S. Genomics since October 1999. Dr. Petrillo joined CB Health Ventures as a General Partner after serving as a Senior Consultant and Founding Partner of the Health Care Commercialization Group at Fletcher Spaght, a strategy consulting firm. He brings over ten years of experience in advising numerous major academic centers and multinational pharmaceutical, information technology, biotechnology firms, medical services and device, and venture capital companies. Dr. Petrillo received his undergraduate degree from Tufts University and a M.D. from Tufts University School of Medicine. He completed his internship, residency, and fellowship training in General Internal Medicine Harvard Medical School and presently serves as an Adjunct Assistant Professor of Medicine at the Boston University School of Medicine and Boston Medical Center. He also serves on the Board of Directors of Spherics.
 

Dr. Knight is president of Fidelity Biosciences Group, a division of Fidelity Investments that invests private equity in the biopharmaceutical industry. Dr. Knight has worked in the pharmaceutical and biotechnology industries for over thirteen years. Prior to joining Fidelity in 2003, Dr. Knight was president and chief operating officer for EPIX Medical, Inc. in Cambridge, MA. He also served EPIX as chief financial officer and senior vice president of business development. For the six years before joining EPIX, Dr. Knight worked at Arthur D. Little Inc. primarily as a senior consultant in Cambridge and Brussels, Belgium specializing in mergers and acquisitions in the pharmaceutical industry. Prior to 1990, Dr. Knight performed research at AT&T Bell Laboratories (now Lucent Technologies), the National Institute of Neurological and Communicative Diseases and Stroke, and at Yale University. Dr. Knight holds an M.D. from the Yale University School of Medicine and an M.B.A. from the Yale School of Organization and Management. Dr. Knight received a bachelor of science degree in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa in 1983. Dr. Knight currently serves as chairman of the Board of Directors for Veritas Medicine and EnVivo Pharmaceuticals. He also serves on the Board of Directors of Microbia. Previously he was a director at Pharmos, Inc.
 

Dr. Bronstein is Managing Director as Zero Stage Capital and is responsible for life science investments. He has more than a decade of experience as a biotech entrepreneur, corporate executive, and advisor to biomedical and scientific companies. He was co-founder, president, and chief executive officer of Peptimmune, Inc., a venture capital financed biotechnology company developing immunotherapeutics, which was acquired by Genzyme in July 1999. Prior to Peptimmune, he was a senior executive with Seaflower Associates, Inc., a private equity advisory firm in Waltham, MA. From 1989-1993 Dr. Bronstein served as vice president of medical affairs and medical director of BioSurface Technology, Inc., which was acquired by Genzyme Corporation after an initial public offering. Dr. Bronstein began his career as a staff pathologist at the Massachusetts General Hospital and was on the faculty of Harvard Medical School.
 

Mr. Rhodes is a principal at Fidelity Biosciences Group, a division of Fidelity Investments that invests private equity in the biopharmaceutical industry. Prior to joining Fidelity, Mr. Rhodes was a vice president with IHCG, a vice president with MPM Capital Advisors, and a consultant with Vertex Partners and Corporate Decisions, Inc. (since acquired by Mercer Management Consulting). In addition to his private equity and transactional experience, he has worked on a broad range of research, development and commercialization projects including the $465M Bayer-Millennium target discovery partnership, the launch of Taxotere, a blockbuster oncology product, and the re-design and implementation of Wyeth's sales force structure. He has a B.A. from Yale University and an M.B.A. from the Wharton School at the University of Pennsylvania. Mr. Rhodes is currently a Chief Business Officer and a Director on the Board of EnVivo Pharmaceuticals.
 

Jim has more than 20 years experience investing in and advising successful early stage companies. Over the past 15 years, Jim has served on the Boards of more than 30 public and private companies in the life sciences, remote data acquisition and data distribution fields. Prior to the creation of the Still River Management Company, from 1985 to 1993, Jim was a General Partner of Fleet Financial Group's venture capital funds, Fleet Venture Partners I through IV. Early in his career he was an administrative dean at Harvard Business School. Jim has recently served on the Boards of Bus-Tech, Inc., Combrio, Inc., Global Communication Devices, Inc.; KVH Industries, MEMSIC Inc., PAREXEL International, Physiometrix, Stargus, Inc., Tracer Technologies Inc., US Genomics Inc. and Xanthus Life Sciences. Jim received an MBA from Harvard Business School and a BA from Oberlin College.